Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

Annals of the Rheumatic Diseases

Volumn 64, Issue 10, 2005, Pages 1414-1420

  Askling, J ^a,b   Fored, C M ^b   Baecklund, E ^c   Brandt, L ^b   Backlin, C ^d   Ekbom, A ^b   Sundstrom C ^d   Bertilsson, L ^e   Coster L ^f   Geborek, P ^g   Jacobsson, L T ^g   Lindblad, S ^b   Lysholm, J ^h   Rantapaa Dahlqvist S ⁱ   Saxne, T ^g   Klareskog, L ^b   Feltelius, N ^b,j  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h FALUN HOSPITAL   (Sweden)

ⁱ UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^j MEDICAL PRODUCTS AGENCY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL RESPONSE MODIFIER; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; B CELL LYMPHOMA; CANCER REGISTRY; CANCER RISK; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG INDUCED CANCER; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEMATOPOIETIC SYSTEM TUMOR; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOMA; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PLASMACYTOMA; POLYCYTHEMIA VERA; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SWEDEN; TREATMENT OUTCOME; ADOLESCENT; ARTICLE; BLOOD DISEASE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; EPIDEMIOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; EPIDEMIOLOGIC METHODS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27744520447     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.033241     Document Type: Review

References (36)

1. Ekstrom K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003;48:963-70.
2. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.
3. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.
4. Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985;78:29-32.
5. Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 1984;43:128-31.
6. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
7. Baecklund E, Ekbom A, Feltelius N, Iliadou A, Backlin C, Askling J, et al. Disease activity, but not DMARD use, increases the risk for malignant lymphoma in rheumatoid arthritis: a case-control study of 378 RA lymphoma patients. Ann Rheum Dis 2004;63(suppl 1):103.
8. Baecklund E, Sundstrom C, Ekbom A, Catrina AI, Biberfeld P, Feltelius N, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003;48:1543-50.
9. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740-51.
10. Wolfe F. Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis. Arthritis Rheum 1998;41(suppl 9):188.
11. Bendix G, Bjelle A, Holmberg E. Cancer morbidity in rheumatoid arthritis patients treated with Proresid or parenteral gold. Scand J Rheumatol 1995;24:79-84.
12. Gridley G, Klippel JH, Hoover RN, Fraumeni JF. Incidence of cancer among men with the Felty syndrome. Ann Intern Med 1994;120:35-9.
13. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
14. Myllykangas-Luosujarvi R, Aho K, Isomaki H. Mortality from cancer in patients with rheumatoid arthritis. Scand J Rheumatol 1995;24:76-8.
15. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997;40:1580-6.
16. Kauppi M, Pukkala E, Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjogren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997;8:201-4.
17. Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 1995;99:276-81.
18. Danesi R, Del Tacca M. Hematologic toxicity of immunosuppressive treatment. Transplant Proc 2004;36:703-4.
19. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
20. Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 1999;117:1433-7.
21. Safety update on TNF-alpha antagonists. US Food and Drug Administration, Arthritis Drugs Advisory Committee.
22. Ljung T, Karlen P, Schmidt D, Hellstrom PM, Lapidus A, Janczewska I, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53.
23. Kavanaugh A, Keenan G, DeWoody K, Masters P, Hendricks D, Clark H, et al. Long-term follow-up patients treated with remicade in clinical trials [abstract]. Arthritis Rheums 2001;44(suppl):S81.
24. Barton J, Moreland L, Weinblatt M, Genovese M, White B, Whitmore J, et al. Six years of safety and efficacy of etanercept in rheumatoid arthritis [abstract]. Ann Rheum Dis 2004;63(suppl 1):282.
25. Symmons DP. Neoplasms of the immune system in rheumatoid arthritis. Am J Med 1985;78:22-8.
26. Patientregistret 1987-1996 Kvalitet och innehåll. Stockholm: Epidemiologist Centrum, Socialstyrelsen, 1998.
27. Soderlin MK, Borjesson O, Kautiainen H, Skogh T, Leirisalo-Repo M. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis 2002;61:911-15.
28. Feltelius N, Fored CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT, et al. Results from a nationwide post marketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64:246-52.
29. Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 1984;23:305-13.
30. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
31. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson I, Saxne T, et al. TNF blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.
32. Askling J, Brandt L, Bertilsson L, Fored M, Geborek P, Jacobsson L, et al. Risk for lymphomas following TNF-blockade. Comparisons with a nationwide comorbidity database [abstract]. Ann Rheum Dis 2004;63(suppl 1):258.
33. Askling J, Brandt L, Bertilsson L, Feltelius N, Fored M, Geborek P, et al. A National database for comorbidity in RA to evaulate drug-safety. Solid cancers in RA and following anti-TNF treatment [abstract]. Ann Rheum Dis 2004;63(suppl 1):85.
34. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6.
35. Kamel OW, Holly EA, van de Rijn M, Lele C, Sah A. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol 1999;26:1676-80.
36. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 1999;12:200-17.